Global Blood Therapeutics Inc GBT:NASDAQ

RT Quote | NASDAQ | USD
Last | 10/03/22 EDT
68.48quote price arrow up+0.38 (+0.56%)
Volume
3,307,420
52 week range
21.65 - 73.02
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close68.48
  • 52 Week High73.02
  • 52 Week High Date08/05/22
  • 52 Week Low21.65
  • 52 Week Low Date06/13/22

Key Stats

  • Market Cap4.621B
  • Shares Out67.48M
  • 10 Day Average Volume2.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.46
  • YTD % Change133.96

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close68.48
  • 52 Week High73.02
  • 52 Week High Date08/05/22
  • 52 Week Low21.65
  • 52 Week Low Date06/13/22
  • Market Cap4.621B
  • Shares Out67.48M
  • 10 Day Average Volume2.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.46
  • YTD % Change133.96

RATIOS/PROFITABILITY

  • EPS (TTM)-5.00
  • P/E (TTM)-13.70
  • Fwd P/E (NTM)-16.99
  • EBITDA (TTM)-293.19M
  • ROE (TTM)-148.56%
  • Revenue (TTM)234.86M
  • Gross Margin (TTM)98.10%
  • Net Margin (TTM)-137.30%
  • Debt To Equity (MRQ)491.67%

EVENTS

  • Earnings Date11/02/2022(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Global Blood Therapeutics Inc

 

Content From Our Affiliates

Profile

MORE
Global Blood Therapeutics, Inc. is a biopharmaceutical company that discovers, develops and delivers treatments. The Company is focused on Oxbryta (voxelotor), which is the Food and Drug Administration (FDA) approved medicine that inhibits sickle hemoglobin (HbS) polymerization, the root cause of red blood cell sickling in sickle cell disease (SCD). It is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in Phase III development to address...
Ted Love M.D.
President, Chief Executive Officer, Director
Jeffrey Farrow
Chief Financial Officer
Nazila Habibizad
Executive Vice President - Operations
Kim Smith- Whitley M.D.
Executive Vice President, Head of Research and Development
Address
181 OYSTER POINT BLVD
South San Francisco, CA
94080
United States

Top Peers

SYMBOLLASTCHG%CHG
ITCI
Intra-Cellular Therapies Inc
47.76+1.23+2.64%
CYTK
Cytokinetics Inc
51.11+2.66+5.49%
NTLA
Intellia Therapeutics Inc
55.83-0.13-0.23%
CERE
Cerevel Therapeutics Holdings Inc
29.06+0.80+2.83%
ARWR
Arrowhead Pharmaceuticals Inc
33.74+0.69+2.09%